European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Rapid diagnosis of preeclampsia at the point-of-care

Objectif

MOMM Diagnostics conceives a new generation of in-vitro diagnostic tests for early diagnosis of preeclampsia. Preeclampsia remains to this day one of the leading causes for maternal mortality. Early diagnosis is therefore vital to minimize complications and prepare adequately for birth. The startup is developing a solution using microscale solid-state sensors for electrical detection of biomarkers in blood, which would allow the detection of multiple biomarkers, using a single-use cartridge and a hand-held reader for diagnosis of the condition directly where the patients are being taken care of. Technology originating from results of the FETOPEN project RECORD-IT (Project ID: 664786) has shown promising innovation potential. MOMM Diagnostics aims to verify this potential for commercialization by assessing its competitiveness for point of care applications. The technology promises an increased signal to noise ratio at a smaller form factor and lower cost compared to commercially available technologies. The FET Innovation Launchpad will help to consolidate the intellectual property rights and develop a demonstrator to approach investors.

Appel à propositions

H2020-FETOPEN-2018-2020

Voir d’autres projets de cet appel

Sous appel

H2020-FETOPEN-2018-2019-2020-03

Coordinateur

MOMM DIAGNOSTICS GMBH
Contribution nette de l'UE
€ 72 000,00
Adresse
Hochbergerstrasse 60C
4057 Basel
Suisse

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 163 125,00

Participants (1)